by John R. Fischer
, Senior Reporter | June 07, 2021
GE Healthcare has joined the American College of Cardiology’s Applied Health Innovation Consortium to help advance the reach and impact of AI and digital technology in cardiology.
The manufacturer will provide its expertise and technology for cardiovascular care to help the consortium develop new strategies around risk prediction and decision-making in cardiac care.
“Ultimately, this will enable precision health, which is doing the right thing, at the right time for every patient, at scale — with the ultimate goal to provide better outcomes, delivered to more people, more cost efficiently,” said Eigil Samset, chief technology scientist for cardiology solutions at GE Healthcare.
Midwest Hand Surgery Auction Closing 5/26 at 8PM. Hologic Fluoroscan Insight-FD Mini C-Arm, Nuvo Dual-Lamp Surgical Lighting System W/Control Panel, Ritter M11 Ultraclave Automatic Sterilizer & More! 2 Day Women's Treatment Center Auction Coming Soon!
The collaboration will initially focus on challenges around atrial fibrillation management and other care pathways, including for coronary artery disease, valvular heart disease and heart failure. The aim of the consortium is to define challenges, develop AI models and apply research findings to clinical practice that will strengthen clinical workflows around cardiac care.
Among its solutions for advancing cardiac care is GE Healthcare’s Edison platform, which is the basis for many of the company’s AI solutions. The solution applies analytics and advanced algorithms to generate clinical, operational and financial insights. Among its offerings for cardiology are Auto EF 2.0, which uses view recognition to simplify ejection fraction assessment; and Embo ASSIST, a 3D visualization software that simulates injections to help clinicians perform embolization procedures with more confidence.
“In our mission to transform cardiovascular care and improve heart health, GE Healthcare is a great collaborator to help build a roadmap for AI and digital technology that bridges gaps in clinical care,” Dr. John Rumsfeld, ACC chief innovation officer and chief science and quality officer.
ACC recently partnered with BioIntelliSense
on cardiac health in a partnership that combined ACC’s clinical expertise with BioIntelliSense’s BioSticker and medical-grade BioButton wearable devices for early detection of adverse vital sign trends in cardiac patients. It also teamed up with Butterfly Network
to design clinical trials and care pathways to address challenging heart diseases and accelerate the adoption of point-of-care ultrasound in cardiovascular care. Back to HCB News